Long-Term Safety and Efficacy Evaluation of Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis

• Status: Not yet recruiting
• Trial end date: 2025-12-01

Summary

This is a single group, Phase 2, long-term extension study for treatment. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated adult participants with moderate to severe AD who have previously been enrolled in study KY1005-CT05 (DRI17366). Visits during the on-treatment period will be at Week 0, 1, 2, 4 and every 4 weeks (Q4W) thereafter. If remote or telephone visits are considered appropriate for participants instead of clinic visits at the timepoints indicated in the schedule of activities (SoA), home visits (e.g., home nurses, etc) will be required for administration of investigational medicinal product (IMP) and assessment of vital signs. This decision is at the discretion of the investigator.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi